{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"45","upperLimit":"79","value":"63"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"description":"The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true success proportion will be calculated.","dispersionType":"95% Confidence Interval","groups":[{"description":"INDUCTION THERAPY: Patients receive ixazomib citrate PO on days 1, 8, and 15 and cyclophosphamide PO and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.\\>\\> \\>\\> MAINTENANCE THERAPY: Patients receive ixazomib citrate PO on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\\>\\>\n\n\\>\\> Cyclophosphamide: Given PO\\>\\>\n\n\\>\\> Dexamethasone: Given PO\\>\\>\n\n\\>\\> Ixazomib Citrate: Given PO\\>\\>\n\n\\>\\> Laboratory Biomarker Analysis: Correlative studies\\>\\>\n\n\\>\\> Pharmacological Study: Correlative studies\\>\\>\n\n\\>\\> Quality-of-Life Assessment: Ancillary studies\\>\\>\n\n\\>\\> Questionnaire Administration: Ancillary studies","id":"OG000","title":"Treatment (Ixazomib Citrate, Cyclophosphamide, Dexamethasone)"}],"paramType":"NUMBER","populationDescription":"Includes only patients with biopsy proven light chain amyloidosis with organ involvement\\>\\> requiring therapy at baseline","reportingStatus":"POSTED","timeFrame":"Up to 48 weeks","title":"Rate of Complete Response, Very Good Partial Response, or Partial Response (Phase II, Cohort B)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}